Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion

Jessika A. Ralph, Lee P Shulman*

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Late second trimester dilation and evacuation is a challenging subset of surgical abortion. Among the reasons for this is the degree of cervical dilation required to safely extricate fetal parts. Cervical dilation is traditionally achieved by placing multiple sets of osmotic dilators over two or more days prior to the evacuation procedure; however, there is interest in shortening cervical preparation time. The use of adjuvant mifepristone and misoprostol in conjunction with osmotic dilators has been studied for this purpose, and their use demonstrates that adequate cervical dilation can be achieved in less time than with dilators alone. We present a review of the current evidence surrounding adjunctive agents for cervical preparation, and contend that for women presenting for surgical abortion care above 19 weeks gestation, the use of adjunctive mifepristone and/or misoprostol should be strongly considered along with osmotic dilator insertion when cervical preparation in less than 24 h is needed.

Original languageEnglish (US)
Pages (from-to)1246-1251
Number of pages6
JournalAdvances in Therapy
Volume36
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Second Pregnancy Trimester
Dilatation
Misoprostol
Mifepristone
Pregnancy

Keywords

  • Cervical preparation
  • Dilation and evacuation
  • Induced abortion
  • Mifepristone
  • Misoprostol

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{dada815fea3e46bcb2776819d72e9b34,
title = "Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion",
abstract = "Late second trimester dilation and evacuation is a challenging subset of surgical abortion. Among the reasons for this is the degree of cervical dilation required to safely extricate fetal parts. Cervical dilation is traditionally achieved by placing multiple sets of osmotic dilators over two or more days prior to the evacuation procedure; however, there is interest in shortening cervical preparation time. The use of adjuvant mifepristone and misoprostol in conjunction with osmotic dilators has been studied for this purpose, and their use demonstrates that adequate cervical dilation can be achieved in less time than with dilators alone. We present a review of the current evidence surrounding adjunctive agents for cervical preparation, and contend that for women presenting for surgical abortion care above 19 weeks gestation, the use of adjunctive mifepristone and/or misoprostol should be strongly considered along with osmotic dilator insertion when cervical preparation in less than 24 h is needed.",
keywords = "Cervical preparation, Dilation and evacuation, Induced abortion, Mifepristone, Misoprostol",
author = "Ralph, {Jessika A.} and Shulman, {Lee P}",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s12325-019-00953-2",
language = "English (US)",
volume = "36",
pages = "1246--1251",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "6",

}

Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion. / Ralph, Jessika A.; Shulman, Lee P.

In: Advances in Therapy, Vol. 36, No. 6, 01.06.2019, p. 1246-1251.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion

AU - Ralph, Jessika A.

AU - Shulman, Lee P

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Late second trimester dilation and evacuation is a challenging subset of surgical abortion. Among the reasons for this is the degree of cervical dilation required to safely extricate fetal parts. Cervical dilation is traditionally achieved by placing multiple sets of osmotic dilators over two or more days prior to the evacuation procedure; however, there is interest in shortening cervical preparation time. The use of adjuvant mifepristone and misoprostol in conjunction with osmotic dilators has been studied for this purpose, and their use demonstrates that adequate cervical dilation can be achieved in less time than with dilators alone. We present a review of the current evidence surrounding adjunctive agents for cervical preparation, and contend that for women presenting for surgical abortion care above 19 weeks gestation, the use of adjunctive mifepristone and/or misoprostol should be strongly considered along with osmotic dilator insertion when cervical preparation in less than 24 h is needed.

AB - Late second trimester dilation and evacuation is a challenging subset of surgical abortion. Among the reasons for this is the degree of cervical dilation required to safely extricate fetal parts. Cervical dilation is traditionally achieved by placing multiple sets of osmotic dilators over two or more days prior to the evacuation procedure; however, there is interest in shortening cervical preparation time. The use of adjuvant mifepristone and misoprostol in conjunction with osmotic dilators has been studied for this purpose, and their use demonstrates that adequate cervical dilation can be achieved in less time than with dilators alone. We present a review of the current evidence surrounding adjunctive agents for cervical preparation, and contend that for women presenting for surgical abortion care above 19 weeks gestation, the use of adjunctive mifepristone and/or misoprostol should be strongly considered along with osmotic dilator insertion when cervical preparation in less than 24 h is needed.

KW - Cervical preparation

KW - Dilation and evacuation

KW - Induced abortion

KW - Mifepristone

KW - Misoprostol

UR - http://www.scopus.com/inward/record.url?scp=85064704844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064704844&partnerID=8YFLogxK

U2 - 10.1007/s12325-019-00953-2

DO - 10.1007/s12325-019-00953-2

M3 - Review article

C2 - 31004327

AN - SCOPUS:85064704844

VL - 36

SP - 1246

EP - 1251

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 6

ER -